VIDA is modernizing lung and respiratory care through intelligence
VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at vidalung.ai.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 12, 2020 | Series C | $11M | 1 | — | — | Detail |
May 21, 2019 | Debt Financing | $500K | 1 | Iowa Innovation Acceleration Fund | — | Detail |
Dec 20, 2016 | Series B | $5.10M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Iowa Innovation Acceleration Fund | Yes | Debt Financing |
Iowa First Capital Fund | — | Series C |
Iowa Seed Fund | — | Series B |
Northern California Investment Fund | — | Series B |